Prime Medicine, Inc. (PRME)
3.25
-0.14
(-4.13%)
USD |
NASDAQ |
Aug 24, 16:00
3.26
+0.01
(+0.31%)
After-Hours: 20:00
Prime Medicine Enterprise Value : 604.80M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 604.80M |
| August 21, 2026 | 630.11M |
| August 20, 2026 | 603.00M |
| August 19, 2026 | 657.22M |
| August 18, 2026 | 568.66M |
| August 17, 2026 | 590.34M |
| August 14, 2026 | 575.89M |
| August 13, 2026 | 590.34M |
| August 12, 2026 | 595.77M |
| August 11, 2026 | 606.61M |
| August 10, 2026 | 586.73M |
| August 07, 2026 | 574.08M |
| August 06, 2026 | 550.58M |
| August 05, 2026 | 574.08M |
| August 04, 2026 | 556.00M |
| August 03, 2026 | 525.28M |
| July 31, 2026 | 545.16M |
| July 30, 2026 | 563.23M |
| July 29, 2026 | 565.04M |
| July 28, 2026 | 575.89M |
| July 27, 2026 | 561.43M |
| July 24, 2026 | 550.58M |
| July 23, 2026 | 554.20M |
| July 22, 2026 | 575.89M |
| July 21, 2026 | 581.31M |
| Date | Value |
|---|---|
| July 20, 2026 | 568.66M |
| July 17, 2026 | 583.12M |
| July 16, 2026 | 599.38M |
| July 15, 2026 | 648.18M |
| July 14, 2026 | 644.57M |
| July 13, 2026 | 652.70M |
| July 10, 2026 | 700.59M |
| July 09, 2026 | 781.93M |
| July 08, 2026 | 852.41M |
| July 07, 2026 | 738.55M |
| July 06, 2026 | 738.55M |
| July 02, 2026 | 716.86M |
| July 01, 2026 | 720.48M |
| June 30, 2026 | 684.33M |
| June 29, 2026 | 650.90M |
| June 26, 2026 | 598.53M |
| June 25, 2026 | 553.37M |
| June 24, 2026 | 542.54M |
| June 23, 2026 | 564.21M |
| June 22, 2026 | 587.69M |
| June 18, 2026 | 562.40M |
| June 17, 2026 | 549.76M |
| June 16, 2026 | 497.38M |
| June 15, 2026 | 502.80M |
| June 12, 2026 | 480.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 2.020B |
| Twist Bioscience Corp. | 8.751B |
| Sana Biotechnology, Inc. | 1.040B |
| Generate Biomedicines, Inc. | 1.878B |
| Intellia Therapeutics, Inc. | 1.394B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.11M |
| Revenue (Quarterly) | 1.154M |
| Total Expenses (Quarterly) | 43.26M |
| EPS Diluted (Quarterly) | -0.2376 |
| Gross Profit Margin (Quarterly) | -54.68% |
| Profit Margin (Quarterly) | -3.65K% |
| Earnings Yield | -33.40% |
| Normalized Earnings Yield | -33.66 |